Clinical Trials
26 trialsNCT03570827 2026-05-26
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Phase 2 Completed
NCT07605507 2026-05-26
HYPOCx-iRex
Siriraj Hospital
Phase NA Active not recruiting
NCT04172532 2026-05-22
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT03274687 2026-05-20
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT03987386 2026-05-20
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT07595224 2026-05-19
PostOP HYPOCxE
Siriraj Hospital
Phase NA Recruiting
NCT03624478 2026-05-15
Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery
Mayo Clinic
Phase 2 Completed
NCT04068194 2026-05-13
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04310020 2026-05-13
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03972930 2026-05-12
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT04106856 2026-05-12
SHAPER
University of Utah
Phase 1 Active not recruiting
NCT07188532 2026-05-11
BEAR
Mayo Clinic
Phase NA Recruiting
NCT07566156 2026-05-11
EV-309
Astellas Pharma Inc
Phase 3 Recruiting
NCT03486821 2026-05-05
Ultra-hypofractionated Radiation in Prostate Cancer
University of Kansas Medical Center
Phase NA Completed
NCT07097142 2026-05-04
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT06443359 2026-04-20
Hypofractionated Regional Nodal Irradiation in Breast Cancer
Corewell Health East
Phase NA Active not recruiting
NCT05917301 2026-04-17
PRONTO
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Recruiting
NCT07507058 2026-04-02
Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Not yet recruiting
NCT07276360 2026-03-27
HypoRTCx-UG
Uganda Cancer Institute
Phase 2 Recruiting
NCT05318274 2026-03-23
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
Coordinación de Investigación en Salud, Mexico
Phase NA Active not recruiting
NCT04624256 2026-03-13
GARUDA
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
NCT01266642 2026-03-11
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02701153 2026-03-10
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Jonsson Comprehensive Cancer Center
Phase NA Recruiting
NCT04454528 2026-03-10
BreastVAX
Abramson Cancer Center at Penn Medicine
Phase 1/2 Active not recruiting
NCT04708067 2026-03-05
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07447570 2026-03-03
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting